NCT01449461 trial: what clinicians have said so far
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
- NCT01449461 ↗
- Completed
- Ariad Pharmaceuticals
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT01449461 (brigatinib in ALK-rearranged non-small-cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01449461 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung
- Interventions
- Brigatinib
- Arms
- Brigatinib 30 mg QD/60 mg QD · Experimental
- Brigatinib 90 mg QD · Experimental
- Brigatinib 120 mg QD/60 mg BID · Experimental
- Brigatinib 90 mg QD-180 mg QD · Experimental
- Brigatinib 180 mg QD/90 mg BID · Experimental
- Brigatinib 240 mg QD/120 mg BID/300 mg QD · Experimental
- Enrollment
- 137
- Primary outcomes
- Recommended Phase 2 Dose (RP2D) of Brigatinib
- Objective Response Rate (ORR)
- Sponsor
- Ariad Pharmaceuticals
- Start
- Sep 20, 2011
- Primary completion
- Nov 16, 2015
- Results posted
- Yes
- Registry record
- NCT01449461 · updated Aug 17, 2021
Publications
linked from the registry- Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 Sep 10;36(26):2693-2701. doi: 10.1200/JCO.2017.77.5841. Epub 2018 May 16. PubMed 29768119
- Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8. PubMed 27836716
- Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013 Feb 1;11(2):161-9. doi: 10.6004/jnccn.2013.0024. PubMed 23411383